Rebecca Lee Reed

US Patent:

20070178066, Aug 2, 2007

Filed:

Nov 3, 2006

Appl. No.:

11/556666

Inventors:

Frederick Hall - Glenndale CA, US
John Levy - Newhall CA, US
Rebecca Reed - Newhall CA, US
Erlinda Gordon - Glenndale CA, US

International Classification:

A61K 48/00
C12N 15/86

US Classification:

424093200, 435456000, 977802000

Abstract:

Systems for pathotropic (disease-seeking) targeted gene delivery are provided, including viral particles with extremely high titers. In particular, the viral particles are engineered to specifically deliver therapeutic or diagnostic agents to a disease site, such as cancer metastic sites. Personalized dosing regimens are also provided to treat diseases such as cancer efficaciously with reduced adverse side effects.

US Patent:

20090123428, May 14, 2009

Filed:

Sep 22, 2008

Appl. No.:

12/235592

Inventors:

Frederick L. Hall - Glendale CA, US
John P. Levy - Newhall CA, US
Rebecca A. Reed - Newhall CA, US
Erlinda M. Gordon - Glendale CA, US

International Classification:

A61K 35/76
C12N 15/00

US Classification:

424 932, 4353201

Abstract:

Systems for pathotropic (disease-seeking) targeted gene delivery are provided, including viral particles with extremely high titers. In particular, the viral particles are engineered to specifically deliver therapeutic or diagnostic agents to a disease site, such as cancer metastic sites. Personalized dosing regimens are also provided to treat diseases such as cancer efficaciously with reduced adverse side effects.

US Patent:

20100016413, Jan 21, 2010

Filed:

Nov 5, 2007

Appl. No.:

12/446976

Inventors:

Frederick L. Hall - Glendale CA, US
John P. Levy - Corona CA, US
Rebecca A. Reed - Canyon Country CA, US
Erlinda M. Gordon - Glendale CA, US

International Classification:

A61K 31/7088
C12N 15/63
A61P 35/00

US Classification:

514 44 R, 4353201

Abstract:

Systems for pathotropic (disease-seeking) targeted gene delivery are provided, including viral particles with extremely high titers. In particular, the viral particles are engineered to specifically deliver therapeutic or diagnostic agents to a disease site, such as cancer metastic sites. Personalized dosing regimens are also provided to treat diseases such as cancer efficaciously with reduced adverse side effects.

US Patent:

20220401581, Dec 22, 2022

Filed:

Jun 17, 2022

Appl. No.:

17/843896

Inventors:

- San Marino CA, US
Rebecca A. REED - Sherman Oaks CA, US
Joseph McNULTY - Pasadena CA, US

International Classification:

A61K 48/00
C12N 9/12
A61K 31/713
A61K 31/522
C07K 14/005
C12N 15/86

Abstract:

Nucleic acid sequences encoding improved Herpes Simplex Virus Thymidine Kinases are provided, including their use in diagnostic and therapeutic applications. The thymidine kinases may be mutated using conservative mutations, non-conservative mutations, or both. Also provided are gene therapeutic systems, including viral and retroviral particles.

US Patent:

20230041229, Feb 9, 2023

Filed:

Dec 23, 2020

Appl. No.:

17/788525

Inventors:

- Thousand Oaks CA, US
Lara BADEN - Woodland Hills CA, US
Rebecca REED - Sherman Oaks CA, US
Bhushan GARWARE - Pune, IN
Chinmay SAVADIKAR - Pune, IN
Anurag PALKAR - Pune, IN
Paul PAGANO - Moorpark CA, US

International Classification:

G06T 7/00
G16H 15/00
G01N 21/64

Abstract:

In some embodiments, a non-transitory processor-readable medium stores code representing instructions to be executed by a processor. The code includes code to cause the processor to receive a plurality of sets of images associated with a sample treated with fluorescence in situ hybridization (FISH) probes. Each image from that set of images is associated with a different focal length using a fluorescence microscope. Each FISH probe can selectively bind to a unique location on chromosomal DNA in the sample. The code further causes the processor to identify cell nuclei in the images. The code further causes the processor to apply a convolutional neural network (CNN) to each set of images. The CNN is configured to identify a probe indication from a plurality of probe indications for that set of images. The code further causes the processor to identify the sample as containing circulating tumor cells.

US Patent:

20200179533, Jun 11, 2020

Filed:

Feb 21, 2020

Appl. No.:

16/798198

Inventors:

- San Marino CA, US
Rebecca A. REED - Sherman Oaks CA, US
Joseph McNULTY - Pasadena CA, US
Robert G. JOHNSON - Pasadena CA, US

International Classification:

A61K 48/00
C07K 14/005
A61K 31/522
A61K 31/713
C12N 9/12

Abstract:

Nucleic acid sequences encoding improved Herpes Simplex Virus Thymidine Kinases are provided, including their use in diagnostic and therapeutic applications. The thymidine kinases may be mutated using conservative mutations, non-conservative mutations, or both. Also provided are gene therapeutic systems, including viral and retroviral particles.

US Patent:

20190328904, Oct 31, 2019

Filed:

Jul 12, 2019

Appl. No.:

16/510731

Inventors:

- San Marino CA, US
Rebecca A. REED - Sherman Oaks CA, US
Joseph MCNULTY - Pasadena CA, US

International Classification:

A61K 48/00
A61K 31/713
C07K 14/005
C12N 9/12
A61K 31/522

Abstract:

Nucleic acid sequences encoding improved Herpes Simplex Virus Thymidine Kinases are provided, including their use in diagnostic and therapeutic applications. The thymidine kinases may be mutated using conservative mutations, non-conservative mutations, or both. Also provided are gene therapeutic systems, including viral and retroviral particles.

US Patent:

20180264137, Sep 20, 2018

Filed:

May 31, 2018

Appl. No.:

15/994999

Inventors:

- San Marino CA, US
Rebecca A. REED - Sherman Oaks CA, US
Joseph MCNULTY - Pasadena CA, US

International Classification:

A61K 48/00
C12N 9/12
A61K 31/713
A61K 31/522
C07K 14/005

Abstract:

Nucleic acid sequences encoding improved Herpes Simplex Virus Thymidine Kinases are provided, including their use in diagnostic and therapeutic applications. The thymidine kinases may be mutated using conservative mutations, non-conservative mutations, or both. Also provided are gene therapeutic systems, including viral and retroviral particles.